SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff is being linked by traders to fears that Democratic control could constrain AI and data-center expansion, weighing on tech-heavy indexes. Others see an overdue valuation reset or forced selling, and debate whether the drop is a buying opportunity or a sign of further losses.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp tech-led selloff, which traders largely link to fears that the midterm results could bring tighter AI and data-center rules; no policy change is confirmed. The community is split between calling the move an overreaction and buying the dip, and warning that it reflects a deeper unwind in AI valuations and could extend further.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broad chip and AI-stock selloff as traders fear tighter AI regulation and delayed data-center projects could slow infrastructure spending; concerns about the sustainability of AI investment are adding pressure. The community is split between investors treating the drop as a buying opportunity and bears arguing that the AI trade is a bubble.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns sharp selloff is being tied by traders to fears that Democratic gains and calls for tighter AI regulation could slow data-center expansion and chip demand, alongside a broader retreat from AI and semiconductor stocks. The community is divided between viewing the decline as an overreaction and buying opportunity supported by Microns fundamentals, and warning that the AI trade may be unwinding further.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Fears that Democratic control of Congress could bring tighter AI regulation and slow data-center construction are driving a broad selloff in SNDK and other memory and semiconductor stocks. Traders are split between viewing the decline as an overreaction to policy uncertainty and strong business fundamentals, and warning that AI spending or memory demand could weaken and the downturn deepen.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff has driven attention to SOXL, with traders linking the rout to fears of an AI-trade unwind and potential restrictions on AI and data-center development after Democrats election gains. The community is split between calling the decline an oversold panic and buying the dip, versus warning that losses could deepen in the 3x daily-leveraged ETF.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A broad tech-market selloff has driven SPCX lower, with traders also attributing pressure to election-related concerns about scrutiny of Musk, government ties and AI infrastructure plans. Bulls call the drop an overreaction and buying opportunity, while bears point to political exposure, valuation and potential insider share unlocks as risks.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broad semiconductor and AI-stock selloff, with traders focused on fears that the new Democratic congressional majority could bring tougher AI and data-center regulation and slow infrastructure spending. The community is split between treating the drop as panic and a buying opportunity, and warning that AI-capex doubts, high valuations, and concentrated customer demand could mean a deeper correction.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Fears that election-related policy and permitting headwinds could slow AI data-center expansion have driven a sharp selloff in Nebius and other neocloud stocks. Traders are divided between calling the decline an overreaction and warning that buildout delays and financing risks could keep pressure on the sector.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a selloff across AI and data-center stocks, as traders worry that Democratic gains could bring tighter permitting and cite a report linking IREN project delays to some of Microsofts lower AI spending; uncertainty ahead of earnings is adding pressure. Bears point to execution and regulatory risks, while some bulls argue the decline is a sector-wide overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 70,605 shares, a growth...

Q1 Earnings Estimate for DWTX Issued By Zacks Research

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Equities researchers at Zacks Research issued their Q1 2026 EPS estimates for Dogwood Therapeutics in a research note issued to investors on...

Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday

Dogwood Therapeutics (NASDAQ:DWTX) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-dogwood-therapeutics-inc-stock...

HC Wainwright Issues Positive Forecast for DWTX Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Dogwood Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of...

What is HC Wainwright's Estimate for DWTX FY2030 Earnings?

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Dogwood Therapeutics in a research...

Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1%

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Get Free Report) saw a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 56,171 shares, a...

Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% - Time to Buy?

Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% - Time to Buy...

What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?

DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence

Equity

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 


Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug 

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.


Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Dogwood Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.</li><li>The company expects to have top-line results from the trial available during the third quarter (Q3) of 2026.&nbsp;</li><li>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026.</li></ul>Dogwood Therapeutics, Inc. (DWTX) said on Monday that patients with chemotherapy induced neuropathic pain (CINP) treated with its painkiller Halneuron demonstrated separation from placebo treated patients in terms of pain improvement over a four-week study. &nbsp;Shares of the company fell 22% at the time of writing and is now poised to log its worst day in over nine months as the update failed to boost investor sentiment.The separation in pain improvement was identified by an independent statistical review committee who reviewed patient treatment data from a mid-stage trial under which 97 patients have completed treatment so far. The company did not <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/22/3209363/0/en/Dogwood-Therapeutics-Announces-Positive-Interim-Phase-2b-Clinical-Trial-Results-in-Chemotherapy-Induced-Neuropathic-Pain.html">detail </a>the scale of pain improvement observed in the analysis.The company expects to have top-line results available during the third quarter (Q3) of 2026.Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.<h2 class="st-heading-2">Company Sounds Optimism</h2>According to Dogwood, current study patient enrollment trends are projected to provide statistical power of approximately 80% to 85% to detect a Halneuron treatment difference.“Extrapolation of the current Phase 2b study trends has the potential to represent the first statistically significant trial involving CINP patients under FDA chronic pain study guidance,” said CEO Greg Duncan.Halneuron is Dogwood’s lead product candidate and has been granted fast track designation from the FDA for the treatment of CINP. Last month, the company confirmed enrollment of 100 patients in the mid-stage study for Halneuron. The company is targeting enrolling 200 patients in the study in total.“We are hopeful that positive outcomes in this ongoing Phase 2b trial will set the stage for a Phase 3 registration program in CINP, providing a needed therapeutic option for this patient population of cancer survivors,” Chief Medical Officer Michael Gendreau said on Monday.<h2 class="st-heading-2">Limited Operational Runway</h2>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026, before it can announce the results of the ongoing Halneuron trial. &nbsp;The company reported a third quarter basic and diluted net loss per share of $8.20, compared to an analyst estimate of a loss of $1.58 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DWTX fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user now expects the stock to drop as low as $2.<stembedurl>https://www.stocktwits.com/hammerfall43/message/639878419</stembedurl><a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> has nearly doubled this year. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-hits-record-high-as-elon-musk-hints-at-fsd-launch-in-uae-next-month-amid-2018-pay-package-boost/cLeFNmTREMq">Tesla Stock Hits Record High As Elon Musk Hints At FSD Launch In UAE Next Month Amid 2018 Pay Package Boost</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 

Current Price	$0.91
Prev Close	$1.03
Open	$1.05
Dividend Yield	0.00%
50-Day Moving Average	$1.59
Beta	0.70
Avg. Volume	73,096.86
PE Ratio	-0.12

52-Week High	$7.04
52-Week Low	$0.901
Market Capitalization	$39.37M
EPS (Annual)	-$7.14
Price to Book	0.51
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DWTX Fundamentals